PFE
Pfizer Inc
27.70$
+0.1%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 34.1% | 26.2% | 22.7% | 23.9% | 31.3% | 19.6% | 22.7% | 32.9% | 26.0% | 19.1% | 23.6% | 20.6% | |
| 2.0% | 2.2% | 1.5% | 0.8% | 0.7% | 0.8% | 1.2% | 1.1% | 0.2% | 1.3% | 0.5% | 0.5% | |
| 21.3% | 13.9% | 10.4% | 11.6% | 11.8% | 5.9% | 7.9% | 17.1% | 11.5% | 5.6% | 9.6% | 6.5% | |
| 5.1% | 6.5% | 6.6% | 6.6% | 7.2% | 7.2% | 7.3% | 8.7% | 7.4% | 4.9% | 6.9% | 7.6% | |
| 3.3% | 4.5% | 4.0% | 4.4% | 4.7% | 4.9% | 5.2% | 5.0% | 4.6% | 4.5% | 5.1% | 5.1% | |
| 6.9% | 8.2% | 7.8% | 8.1% | 8.4% | 8.3% | 9.0% | 8.2% | 8.3% | 8.4% | 9.7% | 10.3% | |
| 24.9% | 28.8% | 31.7% | 32.6% | 33.5% | 35.0% | 32.1% | 27.1% | 26.1% | 29.9% | 32.1% | 34.2% | |
| 20.8% | 24.1% | 30.7% | 28.4% | 22.1% | 21.1% | 18.5% | 13.9% | 22.0% | 28.7% | 26.0% | 25.8% | |
| 57.7% | 61.2% | 65.1% | 58.3% | 60.0% | 62.1% | 58.8% | 57.3% | 51.4% | 60.6% | 58.5% | 58.3% | |
| 12.8% | 17.6% | 18.1% | 17.7% | 20.0% | 22.3% | 16.8% | 23.5% | 21.4% | 21.1% | 20.1% | 17.8% | |
| 3.0% | 6.1% | 6.2% | 5.8% | 5.5% | 9.7% | 1.8% | 1.2% | 1.5% | 4.8% | 3.4% | 1.7% | |
| 2.0% | 2.2% | 2.6% | 2.7% | 2.9% | 2.5% | 2.8% | 3.1% | 3.5% | 3.0% | 2.6% | 2.5% | |
| 18.6% | 17.2% | 18.3% | 19.5% | 20.6% | 21.5% | 24.1% | 19.9% | 16.7% | 26.7% | 26.6% | 29.2% | |
| 42.3% | 38.8% | 34.9% | 41.7% | 40.0% | 37.9% | 41.2% | 42.7% | 48.6% | 39.4% | 41.3% | 41.5% | |
| 42.6% | 43.0% | 41.8% | 49.6% | 56.2% | 58.3% | 62.7% | 57.0% | 63.7% | 52.3% | 54.7% | 55.1% | |
| 0.8% | 0.7% | 0.7% | 0.7% | 3.7% | 3.4% | 3.7% | 3.1% | 2.9% | 2.5% | 2.7% | 2.7% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.